• Explore /
  • Poster
  • / Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104).

Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104).

Abstract Poster

Authors

Stefan Boeck

Stefan Boeck

Department of Internal Medicine III and Comprehens

Stefan Boeck , Steffen Ormanns , Ruediger Laubender , Andreas Jung , Jens Siveke , Michael Haas , Jens Neumann , Ursula Vehling-Kaiser , Cornelia Winkelmann , Ludwig Fischer von Weikersthal , Michael Clemens , Thomas Gauler , Angela Marten , Stefan Klein , Georgi Kojouharoff , Michael Geissler , Tim Greten , Thomas Kirchner , Volker Heinemann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Translational Research

Clinical Trial Registration Number

NCT00440167

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr189)

DOI

10.1200/jco.2013.31.4_suppl.189

Abstract #

189

Poster Bd #

A49

Abstract Disclosures

Similar Posters

First Author: S. H. Boeck

First Author: Jennifer Brooke Goldstein

First Author: Erkut Borazanci

First Author: Michael Haas